Krystal Biotech (KRYS) EBT (2016 - 2026)

Krystal Biotech (KRYS) has 11 years of EBT data on file, last reported at $61.4 million in Q1 2026.

• For the quarter ending Q1 2026, EBT rose 40.93% year-over-year to $61.4 million; the trailing twelve-month figure through Mar 2026 stood at $207.3 million (up 50.21% YoY), and the FY2025 full-year result was $189.5 million, up 98.7% from the prior year.
• EBT climbed to $61.4 million in Q1 2026, from $51.1 million in the prior quarter.
• In the past five years, EBT ranged from a high of $80.7 million in Q3 2023 to a low of -$114.3 million in Q1 2023.
• A 5-year average of $2.9 million and a median of $16.0 million in 2024 frame the typical range for EBT.
• Across the five-year window, EBT plunged 173.27% in 2022 and surged 4577.79% in 2025, its largest moves.
• Tracing KRYS's EBT over 5 years: stood at -$34.0 million in 2022, then surged by 131.32% to $10.7 million in 2023, then surged by 356.13% to $48.6 million in 2024, then increased by 5.19% to $51.1 million in 2025, then increased by 20.17% to $61.4 million in 2026.
• Business Quant data shows KRYS's EBT at $61.4 million in Q1 2026, $51.1 million in Q4 2025, and $48.0 million in Q3 2025.